TrialCompass TCL
Back to results
Phase 1RecruitingPriority 4 · Lower priorityNCT06914037

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

ClinicalTrials.gov

Plain-language summary

This Phase 1 trial is testing CHT101 for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join (key eligibility)

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

CHT101 (DRUG): CD70 UCAR-T

Drugs / treatments
CHT101
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

NCT06914037

Phase: Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Phase 1 trial is testing CHT101 for people whose cutaneous T-cell lymphoma (skin lymphoma) has come back or has not responded to previous treatment. The study starts with lower doses to find the safest effective dose before testing in more people. This trial does not currently list US sites.

Who can join

  • Age 18 Years to 70 Years years
  • Lymphoma came back or did not respond to prior treatment
  • Must be well enough for treatment (adequate performance status)
  • May require specific number of prior treatments

What's being tested

CHT101 (DRUG): CD70 UCAR-T

Drugs / treatments: CHT101

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 24 patients

Primary endpoint: Dose-limiting toxicity (DLT); Maximum tolerated dose (MTD)

Ages: 18 Years to 70 Years

Start date: 2025-03-31 | Est. completion: 2028-03-31

Locations

0 US sites · 1 total

Contact

Huilai Zhang | huilaizhangtz@163.com | +86-18622221228

Sponsor: Tianjin Medical University Cancer Institute and Hospital (OTHER)

Tags

CTCL · Relapsed/Refractory

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06914037

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.